Riskpilot← Back to searchSign inGet full accessImmunoIVD AB
ABActiveOrg 5590180732Nacka StrandResearch and experimental development on natural sciences and engineering · NACE 7210Est. 201527 employees
Revenue 2024
SEK 58,3M
+18% vs 2023
EBITDA margin
28.6%
+108% vs 2023
Equity ratio
42.3%
Financial strength
Net profit 2024
SEK 10,6M
+79% vs 2023
| Revenue | SEK 58,3M | +18% |
| EBITDA | SEK 16,7M | +108% |
| Net profit | SEK 10,6M | +79% |
| Total assets | SEK 42,5M | +29% |
| Equity | SEK 18M | +123% |
| Employees | 27 | — |
Legal name
ImmunoIVD AB
Org number
5590180732
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
24 juni 2015
Share capital
SEK 100 000
Employees
27 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av en av Braesch-Andersen, Sten Paulie, Staffani förening med en av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva utveckla och marknadsföra metoder, processer och produkter som innefattar screening av medfödda fel i immunförsvar, och därmed förenlig verksamhet.
Address
Nacka Strand
Email
ko@immunoivd.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 4 393 | 17 981 | 21 864 | 35 308 | 42 371 | 49 234 | 58 270 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −998 | −4 048 | −3 292 | −3 152 | −725 | −3 168 | 546 | 9 576 | 8 024 | 16 650 |
| Depreciation & amort. | −4 | −169 | −212 | −477 | −986 | −2 078 | −2 043 | −2 481 | −2 244 | −2 271 |
| EBIT | −1 002 | −4 217 | −3 504 | −3 629 | −1 711 | −5 246 | −1 497 | 7 095 | 5 780 | 14 379 |
| Net financials | — | — | −60 | −173 | −377 | −1 836 | −1 330 | −1 536 | −1 375 | −976 |
| Profit before tax | −1 002 | −4 217 | −3 565 | −3 802 | −2 087 | −6 164 | −2 827 | 5 560 | 4 405 | 13 402 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | 1 236 | 1 543 | −2 771 |
| Net profit | −1 002 | −4 217 | −3 565 | −3 802 | −2 087 | −6 164 | −2 827 | 6 796 | 5 948 | 10 631 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2 877 | 2 070 | 2 234 | 17 002 | 14 113 | 16 026 | 25 202 | 31 240 | 32 893 | 42 539 |
| Equity | 2 048 | 831 | 916 | 11 664 | 3 427 | 762 | 136 | 7 111 | 8 069 | 17 996 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 829 | 1 239 | 1 318 | 5 338 | 10 687 | 15 263 | 25 066 | 24 129 | 24 824 | 24 544 |
| Total debt | 829 | 1 239 | 1 318 | 5 338 | 10 687 | 15 263 | 25 066 | 24 129 | 24 824 | 24 544 |
EBITDA margin
28.6%
This company
15.8%
Market median
+81% vs market
20152024
Equity ratio
42.3%
This company
38.2%
Market median
+11% vs market
20152024
Return on equity
59.1%
This company
18.4%
Market median
+221% vs market
20152024
Net profit margin
18.2%
This company
8.1%
Market median
+125% vs market
20152024
Asset turnover
1.37×
This company
1.12×
Market median
+22% vs market
20152024
Debt / equity
1.36×
This company
0.62×
Market median
-119% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-06-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ED Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
GL Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Pabros AB | Company | 87.0% | 87.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pabros AB
ImmunoIVD AB Board members of ImmunoIVD AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erna Domsgen | Chief Executive Officer | 0 companies |
| Gabriel Lars Dan Forssenius | Chief Auditor | 0 companies |
| Lars-Göran Lennart Hammarström | Board of Directors | 0 companies |
| Sten Braesch-Andersen | Chairman | 0 companies |
| Staffan Paulie | Board of Directors | 0 companies |
| Kjell Olov Östrand | Deputy Board Member | 0 companies |
| Stephan Michael Borte | Board of Directors | 0 companies |